PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

Journal of Clinical Investigation

Volumn 118, Issue 11, 2008, Pages 3762-3774

  Silva, Ana ^a   Yunes, J Andrés ^b   Cardoso, Bruno A ^a   Martins, Leila R ^a   Jotta, Patrícia Y ^b   Abecasis, Miguel ^c   Nowill, Alexandre E ^d   Leslie, Nick R ^e   Cardoso, Angelo A ^f   Barata, Joao T ^a,g  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b CENTRO INFANTIL BOLDRINI   (Brazil)

^c HOSPITAL DE SANTA CRUZ   (Portugal)

^d UNIVERSITY OF CAMPINAS   (Brazil)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASEIN KINASE II; ENZYME INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; GENE; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PTEN GENE; SIGNAL TRANSDUCTION; T CELL LEUKEMIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MODELS, BIOLOGICAL; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE;

EID: 55849138418     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34616     Document Type: Article

References (65)

1. Vivanco, I., Sawyers, C.L. 2002. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:489-501.
2. Luo, J., Manning, B.D., Cantley, L.C. 2003. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 4:257-262.
3. Barata, J.T., et al. 2004. Activation of PI3K Is Indispensable for Interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J. Exp. Med. 200:659-669.
4. Xu, Q., Simpson, S.E., Scialla, T.J., Bagg, A., Carroll, M. 2003. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 102:972-980.
5. Hsu, J., et al. 2001. The AKT kinase is activated in multiple myeloma tumor cells. Blood. 98:2853-2855.
6. Schade, A.E., Powers, J.J., Wlodarski, M.W., Maciejewski, J.P. 2006. Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood. 107:4834-4840.
7. Ali, I.U., Schriml, L.M., Dean, M. 1999. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl. Cancer Inst. 91:1922-1932.
8. Sansal, I., Sellers, W.R. 2004. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22:2954-2963.
9. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., Pandolfi, P.P. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:348-355.
10. Podsypanina, K., et al. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. U. S. A. 96:1563-1568.
11. Suzuki, A., et al. 2001. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 14:523-534.
12. Yilmaz, O.H., et al. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 441:475-482.
13. Zhang, J., et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 441:518-522.
14. Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E.S., Raffeld, M. 1998. PTEN gene alterations in lymphoid neoplasms. Blood. 92:3410-3415.
15. Shan, X., et al. 2000. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol. Cell. Biol. 20:6945-6957.
16. Xu, Z., Stokoe, D., Kane, L.P., Weiss, A. 2002. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ. 13:285-296.
17. Cully, M., You, H., Levine, A.J., Mak, T.W. 2006. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer. 6:184-192.
18. Lee, S.R., et al. 2002. Reversible inactivation of the tumor suppressor PTEN by H2O2. J. Biol. Chem. 277:20336-20342.
19. Leslie, N.R., et al. 2003. Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J. 22:5501-5510.
20. Vazquez, F., Ramaswamy, S., Nakamura, N., Sellers, W.R. 2000. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 20:5010-5018.
21. Torres, J., Pulido, R. 2001. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 276:993-998.
22. Miller, S.J., Lou, D.Y., Seldin, D.C., Lane, W.S., Neel, B.G. 2002. Direct identification of PTEN phosphorylation sites. FEBS Lett. 528:145-153.
23. Tolkacheva, T., et al. 2001. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 61:4985-4989.
24. Daya-Makin, M., et al. 1994. Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res. 54:2262-2268.
25. Landesman-Bollag, E., et al. 2001. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene. 20:3247-3257.
26. Scaglioni, P.P., et al. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 126:269-283.
27. Piazza, F.A., et al. 2006. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 108:1698-1707.
28. Seldin, D.C., Leder, P. 1995. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science. 267:894-897.
29. Szatrowski, T.P., Nathan, C.F. 1991. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51:794-798.
30. Irani, K., et al. 1997. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science. 275:1649-1652.
31. Suh, Y.A., et al. 1999. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 401:79-82.
32. Connor, K.M., et al. 2005. Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidation. J. Biol. Chem. 280:16916-16924.
33. Maser, R.S., et al. 2007. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature. 447:966-971.
34. Ferrando, A.A., et al. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:75-87.
35. Graux, C., Cools, J., Michaux, L., Vandenberghe, P., Hagemeijer, A. 2006. Cytogenetics and molecular genetics of Tcell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 20:1496-1510.
36. Hare, K.J., Jenkinson, E.J., Anderson, G. 2000. An essential role for the IL-7 receptor during intrathymic expansion of the positively selected neonatal T cell repertoire. J. Immunol. 165:2410-2414.
37. Georgescu, M.M., Kirsch, K.H., Akagi, T., Shishido, T., Hanafusa, H. 1999. The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc. Natl. Acad. Sci. U. S. A. 96:10182-10187.
38. Vazquez, F., et al. 2006. Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane. Proc. Natl. Acad. Sci. U. S. A. 103:3633-3638.
39. Palomero, T., et al. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13:1203-1210.
40. Roman-Gomez, J., et al. 2005. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J. Clin. Oncol. 23:7043-7049.
41. Barata, J.T., et al. 2004. IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 103:1891-1900.
42. Di Maira, G., et al. 2005. Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ. 12:668-677.
43. Uddin, S., et al. 2004. Inhibition of phosphatidylinositol 3ι-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem. Biophys. Res. Commun. 320:932-938.
44. Abbott, R.T., et al. 2003. Analysis of the PI-3-Kinase-PTENAKT pathway in human lymphoma and leukemia using a cell line microarray. Mod. Pathol. 16:607-612.
45. Chen, Z., et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725-730.
46. Di Cristofano, A., et al. 2001. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:222-224.
47. Wang, X., et al. 2007. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 128:129-139.
48. Avellino, R., et al. 2005. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood. 106:1400-1406.
49. Dahia, P.L., et al. 1999. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum. Mol. Genet. 8:185-193.
50. Cheong, J.W., et al. 2003. Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br. J. Haematol. 122:454-456.
51. Nakajima, H., et al. 2007. Apoptosis and inactivation of the PI3-kinase pathway by tetrocarcin A in breast cancers. Biochem. Biophys. Res. Commun. 356:260-265.
52. He, L., et al. 2007. Co-existence of high levels of the PTEN protein with enhanced Akt activation in renal cell carcinoma. Biochim. Biophys. Acta. 1772:1134-1142.
53. Kwon, J., et al. 2004. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc. Natl. Acad. Sci. U. S. A. 101:16419-16424.
54. Kops, G.J., et al. 2002. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature. 419:316-321.
55. Tothova, Z., et al. 2007. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 128:325-339.
56. Paik, J.H., et al. 2007. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 128:309-323.
57. Vogt, P.K., Kang, S., Elsliger, M.A., Gymnopoulos, M. 2007. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem. Sci. 32:342-349.
58. Weng, A.P., et al. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 306:269-271.
59. Sade, H., Krishna, S., Sarin, A. 2004. The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J. Biol. Chem. 279:2937-2944.
60. Schneider, U., Schwenk, H.U., Bornkamm, G. 1977. Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer. 19:621-626.
61. Minowada, J., Onuma, T., Moore, G.E. 1972. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J. Natl. Cancer Inst. 49:891-895.
62. Foley, G.E., et al. 1965. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer. 18:522-529.
63. Morikawa, S., Tatsumi, E., Baba, M., Harada, T., Yasuhira, K. 1978. Two E-rosette-forming lymphoid cell lines. Int. J. Cancer. 21:166-170.
64. Uckun, F.M., et al. 1997. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J. Clin. Oncol. 15:2214-2221.
65. Bene, M.C., et al. 1995. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 9:1783-1786.